Trivedi Premal S, Brown Matthew A, Rochon Paul J, Ryu Robert K, Johnson D Thor
Vascular and Interventional Radiology, University of Colorado, Anschutz Medical Center, Aurora, Colorado.
Vascular and Interventional Radiology, University of Colorado, Anschutz Medical Center, Aurora, Colorado.
J Am Coll Radiol. 2020 Feb;17(2):231-237. doi: 10.1016/j.jacr.2019.08.020. Epub 2019 Sep 18.
The aim of this study was to evaluate inpatient mortality after transjugular intrahepatic portosystemic shunt (TIPS) creation compared with medical management (MM) in patients with hepatorenal syndrome (HRS).
Patients with cirrhosis admitted with HRS between 2005 and 2014 were identified using associated International Classification of Diseases, Ninth Revision, codes in the National Inpatient Sample (n = 153,112). Non-TIPS candidates and patients with parenchymal renal disease were excluded (n = 73,454). The remaining admissions were assigned to groups of TIPS (International Classification of Diseases, Ninth Revision, code 39.1; n = 971) or MM (n = 78,687). Inpatient mortality was analyzed by treatment type and patient gender using χ tests. Logistic regression was performed to control for baseline differences in patient demographics, comorbid disease, and pretreatment mortality risk.
Baseline patient demographics were similar. Patients treated medically had higher baseline disease severity (median mortality risk score, 8.3 with MM versus 6.1 with TIPS; P < .01). Inpatient mortality was strongly modified by patient gender. TIPS creation conferred inpatient mortality benefit in men (28% of the MM group versus 10% of the TIPS group, P < .01) independent of all covariates (odds ratio, 0.4; 95% confidence interval, 0.17-0.78; P < .01). Women treated with TIPS creation experienced no mortality benefit (29% MM versus 32% TIPS; odds ratio, 1.5; 95% confidence interval, 0.75-3.23; P = .23).
TIPS creation is associated with reduced inpatient mortality in men, but not women, admitted with HRS. Drivers of this gender-based disparity are currently unclear and warrant focused investigation.
本研究旨在评估经颈静脉肝内门体分流术(TIPS)与药物治疗(MM)相比,对肝肾综合征(HRS)患者住院死亡率的影响。
利用国家住院患者样本中相关的国际疾病分类第九版编码,确定2005年至2014年间因HRS入院的肝硬化患者(n = 153,112)。排除非TIPS候选患者和实质性肾病患者(n = 73,454)。其余入院患者分为TIPS组(国际疾病分类第九版编码39.1;n = 971)或MM组(n = 78,687)。采用χ检验按治疗类型和患者性别分析住院死亡率。进行逻辑回归以控制患者人口统计学、合并症和治疗前死亡风险的基线差异。
基线患者人口统计学特征相似。接受药物治疗的患者基线疾病严重程度更高(中位死亡风险评分,MM组为8.3,TIPS组为6.1;P <.01)。住院死亡率受患者性别的显著影响。TIPS手术使男性患者住院死亡率降低(MM组为28%,TIPS组为10%,P <.01),且不受所有协变量影响(比值比,0.4;95%置信区间,0.17 - 0.78;P <.01)。接受TIPS手术的女性患者未获得死亡率益处(MM组为29%,TIPS组为32%;比值比,1.5;95%置信区间,0.75 - 3.23;P =.23)。
对于因HRS入院的男性患者,TIPS手术与降低住院死亡率相关,但女性患者并非如此。目前尚不清楚这种基于性别的差异的驱动因素,值得进行重点研究。